GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Follicular LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT01691898
- Locations
- 🇮🇹
Azienda Ospedale San Giovanni, Torino, Piemonte, Italy
🇺🇸Texas Oncology, P.A. - Tyler; Tyler Cancer Center, Tyler, Texas, United States
🇨🇦McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01685892
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States
🇺🇸Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01671904
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of California San Diego Medical Center, La Jolla, California, United States
🇫🇷Hopital Saint Eloi, Montpellier, France
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT01662063
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01656642
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT01652482
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT01633970
- Locations
- 🇺🇸
Uni of Chicago, Chicago, Illinois, United States
🇺🇸Carolina BioOncology Institute; Can Therapy & Res Ctr, Huntersville, North Carolina, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
- Conditions
- Breast Cancer
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1007
- Registration Number
- NCT01615068
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Allegheny General Hospital; Transplantation Services, Pittsburgh, Pennsylvania, United States
🇺🇸Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
- Conditions
- Granulomatosis With PolyangiitisMicroscopic Polyangiitis
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01613599
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins Asthma&Allergy, Baltimore, Maryland, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
- Conditions
- Coronary Heart Disease
- Interventions
- Drug: MPSK3169ADrug: Placebo
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 248
- Registration Number
- NCT01609140